Reflux inhibitor drugs: an emerging novel therapy for gastroesophageal reflux disease.
about
The oesophagus and cough: laryngo-pharyngeal reflux, microaspiration and vagal reflexesEvolving pharmacological approaches in gastroesophageal reflux disease.The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease.Medical Treatment of Gastroesophageal Reflux Disease.
P2860
Reflux inhibitor drugs: an emerging novel therapy for gastroesophageal reflux disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reflux inhibitor drugs: an emerging novel therapy for gastroesophageal reflux disease.
@en
Reflux inhibitor drugs: an emerging novel therapy for gastroesophageal reflux disease.
@nl
type
label
Reflux inhibitor drugs: an emerging novel therapy for gastroesophageal reflux disease.
@en
Reflux inhibitor drugs: an emerging novel therapy for gastroesophageal reflux disease.
@nl
prefLabel
Reflux inhibitor drugs: an emerging novel therapy for gastroesophageal reflux disease.
@en
Reflux inhibitor drugs: an emerging novel therapy for gastroesophageal reflux disease.
@nl
P1476
Reflux inhibitor drugs: an emerging novel therapy for gastroesophageal reflux disease.
@en
P2093
P356
10.1111/J.1751-2980.2010.00418.X
P577
2010-04-01T00:00:00Z